Balance Sheet

Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Avalo Therapeutics (AVTX) Acquisitions (2017 - 2024)

Avalo Therapeutics' Acquisitions history spans 3 years, with the latest figure at $356000.0 for Q1 2024.

For Q1 2024, Acquisitions changed N/A year-over-year to $356000.0; the TTM value through Dec 2024 reached $356000.0, changed N/A, while the annual FY2024 figure was $356000.0, N/A changed from the prior year.
Acquisitions reached $356000.0 in Q1 2024 per AVTX's latest filing, up from $1.0 in the prior quarter.
In the past five years, Acquisitions ranged from a high of $356000.0 in Q1 2024 to a low of $356000.0 in Q1 2024.